# 1 Deciphering autoantibody landscape of systemic sclerosis through systems-based

#### 2 approach: insights from a B-cell depletion clinical trial

- 3
- 4 Kazuki M Matsuda, MD, PhD,<sup>1</sup> Satoshi Ebata, MD, PhD,<sup>1</sup> Kazuhiro Iwadoh, MD,
- 5 PhD,<sup>1</sup> Hirohito Kotani, MD, PhD,<sup>1</sup> Teruyoshi Hisamoto, MD, PhD,<sup>1</sup> Ai Kuzumi, MD,
- 6 PhD,<sup>1</sup> Takemichi Fukasawa MD, PhD,<sup>1,2</sup> Asako Yoshizaki-Ogawa, MD, PhD,<sup>1</sup> Shinichi
- 7 Sato, MD, PhD, <sup>1</sup> Ayumi Yoshizaki, MD, PhD<sup>1,2#</sup>
- 8
- 9 1. Department of Dermatology, The University of Tokyo Graduate School of Medicine,
- 10 Tokyo, Japan
- 11 2. Department of Clinical Cannabinoid Research, The University of Tokyo Graduate
- 12 School of Medicine, Tokyo, Japan

13

#### 14 # Corresponding author

15 Ayumi Yoshizaki, MD, PhD

- 16 Department of Dermatology and Department of Clinical Cannabinoid Research, The
- 17 University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo,
- 18 Japan, 1138655
- 19 Phone: +81-3-3815-5411
- 20 ORCID: 0000-0002-8194-9140
- 21 E-mail: <u>ayuyoshi@me.com</u>
- 22 \_\_\_\_\_

### 23 Abstract

24	Systemic sclerosis (SSc) is a progressive fibrotic disorder with a high mortality
25	rate, characterized by extensive autoantibody production. Despite recent advancements,
26	effective treatments remain limited. Rituximab (RTX), a B-cell depleting agent, has
27	shown promise in clinical trials. The DESIRES trial highlighted the reduction in
28	modified Rodnan Skin Score (mRSS) and the association between serum
29	immunoglobulin levels and RTX responsiveness. We employed proteome-wide
30	autoantibody screening (PWAS) using wet protein arrays (WPAs) that display 13,455
31	human autoantigens to analyze serum samples from SSc patients in the DESIRES trial
32	and age- and sex-matched healthy controls (HCs). As a result, the sum of autoantibody
33	levels (SAL) was significantly higher in SSc patients compared to HCs. High
34	responders (HRs) to RTX showed a greater initial SAL and significant reductions
35	post-treatment, unlike low responders (LRs). Machine learning identified specific
36	autoantibodies linked to disease status, and 58 autoantibodies were identified as
37	clinically relevant. Some of those autoantibodies targeted membrane proteins including
38	G protein-coupled receptors, associated with better differentiation between HRs and
39	LRs. Our findings underscore the significance of autoantibodies in SSc pathogenesis
40	and their potential role in predicting RTX responsiveness. This comprehensive

41 autoantibody profiling could enhance diagnostic and therapeutic strategies, and

42 moreover, better understanding of the pathophysiology of SSc.

43

# 44 Introduction

45	Systemic sclerosis (SSc) is a progressive fibrotic disorder that affects both the
46	skin and internal organs. <sup>1</sup> Among connective tissue diseases, it has the poorest
47	prognosis, with an approximate 30% mortality rate within ten years. <sup>2</sup> Historically,
48	treatment options for SSc have been limited. While the exact cause of SSc remains
49	unclear, increasing evidence indicates that B cells play a significant role in the
50	pathogenesis. <sup>3-5</sup> They contribute by producing autoantibodies, secreting unique
51	cytokines, and activating other immune cells. Reflecting this understanding, various
52	B-cell targeting therapeutic modalities, monoclonal antibodies, <sup>6-8</sup> Bruton's tyrosine
53	kinase inhibitors, <sup>9</sup> and chimeric antigen receptor (CAR) T-cell therapies, <sup>10-12</sup> are
54	emerging as promising treatments for SSc.
55	Rituximab (RTX) is a chimeric monoclonal antibody that depletes circulating
56	B cells by targeting the B-cell specific antigen CD20. Previously, we conducted a
57	double-blind, investigator-initiated, randomized, placebo-controlled trial, or the
58	DESIRES trial, <sup>13</sup> which demonstrated significant superiority of RTX over placebo by
59	the absolute reduction of modified Rodnan Skin Score (mRSS) 24 weeks after initiation

60 of the study period. The open-label extension of this trial also revealed the long-term

efficacy and safety of RTX on SSc,<sup>14</sup> as well as the association between decrease in
serum immunoglobulins and greater clinical response to RTX.<sup>15</sup>

63	The emergence of autoantibodies is a prominent feature of SSc, highlighting its
64	nature as an autoimmune disorder. Anti-nuclear antibodies (ANAs), detected through
65	indirect immunofluorescence on HEp-2 cells, are present in more than 90% of patients
66	with SSc. <sup>16</sup> Several ANAs are specific to SSc or are closely associated with distinct
67	clinical subsets. For instance, anti-topoisomerase I antibodies (ATA) are strongly linked
68	to diffuse skin sclerosis and severe interstitial lung disease (ILD), while anti-centromere
69	antibodies (ACA) are primarily associated with limited skin and lung involvement. <sup>17</sup>
70	However, the pathogenicity of these ANAs is debated, as they cannot reach their targets
71	across the plasma and nuclear membranes in vivo. Additionally, the DESIRES trials
72	revealed that serum ATA levels did not decrease, <sup>13,14</sup> indicating that the relationship
73	between serum immunoglobulin levels and responsiveness to RTX cannot be explained
74	by ATA levels.

Herein, we employed our original technique for proteome-wide autoantibody
screening (PWAS) using wet protein arrays (WPAs) that cover approximately 90% of
the human transcriptome.<sup>18,19</sup> This technique has previously been used to develop
multiplex measurements for disease-related autoantibodies,<sup>20,21</sup> identify clinically

79	relevant novel autoantibodies, <sup>22,23</sup> and investigate inter- and intra-molecular epitope
80	spreading during the disease course. We applied PWAS to serum samples from SSc
81	patients who participated in the DESIRES trial, as well as sex- and age-matched healthy
82	controls (HCs). Our aim was to elucidate the autoantibody landscape in SSc and
83	investigate clusters of autoantibodies that contribute to the reduction of serum
84	immunoglobulin levels associated with a good response to RTX in SSc patients. This
85	research seeks to identify novel biomarkers and gain a better understanding of the
86	pathogenesis of SSc.

### 87 **Results**

88 Subjects

89	In the DESIRES trial (NCT04274257), a total of 56 individuals diagnosed with
90	SSc were evenly randomized into two groups: 28 received RTX and 28 received a
91	placebo. <sup>13</sup> Serum samples were collected at the start and after 24 weeks of treatment
92	from participants who completed the term. These samples were reacted with WPAs for
93	PWAS (Figure 1A). After excluding samples that were not suitable for PWAS, such as
94	those containing anti-GST-tag antibodies, the study proceeded with 24 patients in the
95	RTX group and 21 patients in the placebo group. The baseline characteristics of the two
96	groups were comparable (Table 1). An equal number of age- and sex-matched healthy
97	controls (HCs) were also included in the study (Figure 1B).
98	
99	The sum of autoantibody levels
100	We defined the sum of autoantibody levels (SAL) as the total serum
101	concentration of all autoantibodies assessed in our PWAS. SAL was significantly higher
102	in SSc patients compared to HCs at the baseline ( $P < 0.0001$ ; Figure 1C). Subsequently,

- 103 we categorized the RTX treatment group into two subgroups based on their response to
- 104 treatment (**Figure 1D**): high responders (HRs; n = 11) and low responders (LRs; n = 13).

105	Initially, SAL was significantly greater in the HR group compared to the LR group (P $\!<\!$
106	0.05; Figure 1E). Additionally, SAL levels decreased significantly from week 0 to
107	week 24 in the HR group (P < 0.05), whereas changes in the LR group were not
108	statistically significant. This pattern persisted across all age groups (Extended Figure
109	1A). In contrast, serum levels of well-known SSc-related autoantibodies, including
110	anti-topoisomerase I antibodies (ATA), anti-centromere antibodies (ACA), and
111	anti-RNA polymerase III antibodies (ARA), did not follow this trend, as observed both
112	in clinical-standard ELISA tests (Figure 1F) and in our PWAS (Extended Figure 1B).
113	

#### 114 Machine learning

115 To determine which autoantibodies were driving the association between the SAL and disease status, we firstly utilized nine machine learning frameworks. Notably, 116 117 Lasso regression, Ridge regression, SVM with normalization, XGBoost, and LightGBM 118 achieved an area under the receiver-operator characteristics curve (ROC-AUC) 119 exceeding 0.96, demonstrating an almost perfect ability to distinguish between SSc 120 patients and HCs (Table 2). We identified the top 10 features in these six models 121 (Extended Figure 2A), examined their inclusion relationships (Extended Figure 2B), 122 and explored the prevalence of highlighted autoantibodies across a broader range of

123	human disorders using the aUToAntiBody Comprehensive Database (UT-ABCD). <sup>24</sup>
124	Most of these autoantibodies were found to be non-specifically elevated in various
125	pathological conditions, except for well-known SSc-specific autoantibodies such as
126	ATA and ARA (Extended Figure 2C). Attempts to distinguish between HRs and LRs
127	based on pre-treatment autoantibody profiles did not yield satisfactory precision
128	(Extended Table 1).

129

#### 130 Investigating clinically relevant autoantibodies

131 We next sought to identify autoantibodies significantly associated with the 132 clinical features of SSc using the trial data that included longitudinal changes. Initially, 133 we selected autoantibodies that were significantly elevated in SSc patients compared to 134 HCs at baseline (Figure 2A). Next, we chose autoantibodies that were significantly 135 higher in HRs compared to LRs (Figure 2B). Lastly, we focused on autoantibodies 136 whose serum concentrations significantly decreased from week 0 to week 24 in HRs 137 (Figure 2C). As a result, 58 autoantibodies were identified as candidates for clinically 138 relevant autoantibodies in SSc (Figure 2D). Principal component analysis (PCA) 139 indicated that these 58 autoantibodies appear to distinguish HRs at week 0 within the 140 dataset (Figure 2E). The sum of the serum levels of these autoantibodies displayed a

141	pattern like SAL, but in a more pronounced manner (Figure 2F). Consistently,
142	ROC-AUC analysis showed that these 58 autoantibodies provide better differentiation
143	between SSc patients and HCs compared to the complete autoantibody profile (Figure
144	2G), and moreover, distinguish between HRs and LRs with nearly perfect precision
145	(Figure 2H).

146

### 147 *Profiling candidate autoantibodies*

148 To explore the molecular features of the human proteins targeted by the 149 identified candidate autoantibodies, we conducted gene ontology enrichment analyses utilizing Metascape.<sup>25</sup> Notably, whereas established SSc-related autoantibodies 150 151 primarily target intracellular antigens, our findings emphasized membrane proteins 152 associated with processes such as "import across plasma membrane" and "peptide G 153 protein-coupled receptors (GPCRs)" (Figure 3A). There were four autoantibodies 154 linked to each of the processes "import across plasma membrane" and "peptide GPCRs" 155 (Figure 3B). Autoantibodies associated with plasma membrane import included those 156 targeting presenilin 1 (PSEN1), solute carrier family 22 member 2 (SLC22A2), transient 157 receptor potential cation channel subfamily V member 5 (TRPV5), and solute carrier 158 family 46 member 1 (SLC46A1; Figure 3C). The group related to peptide GPCRs

159	comprised autoantibodies against chemokine receptor 8 (CCR8), formyl peptide
160	receptor 1 (FPR1), melanocortin 1 receptor (MC1R), and G protein-coupled receptor 63
161	(GPR63; Figure 3E). The associations between each autoantibody and the clinical
162	characteristics of SSc were detailed in Figures 3D and 3F. We also investigated the
163	distribution of these highlighted autoantibodies in a broader population, utilizing
164	UT-ABCD. As a result, all the items were not specific to SSc (Extended Figure 3).
165	The tissue specificity of the highlighted autoantigens was investigated using
166	publicly available databases. Analysis of multiple human tissues through bulk RNA
167	sequencing data from the Human Protein Atlas <sup>26</sup> revealed that CCR8 and FPR1 are
168	enriched in bone marrow and lymphoid tissues (Extended Figure 4, A and B).
169	Single-cell RNA sequencing data from the Tabula Sapiens project <sup>27</sup> showed that CCR8
170	expression is enhanced in regulatory T cells (Tregs; Extended Figure 4C), while FPR1
171	expression is elevated in neutrophils (Extended Figure 4D). Meanwhile, MC1R
172	expression appeared to be relatively ubiquitous across different tissues.
173	
174	Weighted correlation network analysis

We utilized weighted correlated network analysis (WGCNA)<sup>28</sup> to delve deeper
into the correlations between autoantibodies in SSc. Our study included 135 specimens

177	from SSc patients at weeks 0 and 24, as well as HCs. We constructed a correlation
178	network for all autoantibodies evaluated in our PWAS and identified 57 distinct
179	modules (Figure 4A). The "turquoise" module, which contained ATA, also included
180	half of the candidate autoantibodies: anti-TRPV5, CCR8, MC1R, and GPR63
181	antibodies (Figure 4B). The "darkmagenta" module included ARA. The "tan" module
182	included ACA. The other candidate autoantibodies did not appear in either the
183	"darkmagenta" or "tan" modules. We also conducted gene ontology analyses on the
184	gene lists encoding proteins targeted by autoantibodies within these three modules
185	(Extended Table 2). The Enrichment score was the highest for "mitochondrion
185 186	(Extended Table 2). The Enrichment score was the highest for "mitochondrion organization" in the "turquoise" module (Figure 4C). The enrichment scores for
185 186 187	(Extended Table 2). The Enrichment score was the highest for "mitochondrion organization" in the "turquoise" module (Figure 4C). The enrichment scores for "regulation of cellular response to stress" were highest in the "turquoise" module,
185 186 187 188	(Extended Table 2). The Enrichment score was the highest for "mitochondrion organization" in the "turquoise" module (Figure 4C). The enrichment scores for "regulation of cellular response to stress" were highest in the "turquoise" module, moderate in the "darkmagenta" module, and lowest in the "tan" module. This pattern
185 186 187 188 189	(Extended Table 2). The Enrichment score was the highest for "mitochondrion organization" in the "turquoise" module (Figure 4C). The enrichment scores for "regulation of cellular response to stress" were highest in the "turquoise" module, moderate in the "darkmagenta" module, and lowest in the "tan" module. This pattern aligns with the clinical severity associated with ATA, ARA, and ACA.
185 186 187 188 189 190	(Extended Table 2). The Enrichment score was the highest for "mitochondrion organization" in the "turquoise" module (Figure 4C). The enrichment scores for "regulation of cellular response to stress" were highest in the "turquoise" module, moderate in the "darkmagenta" module, and lowest in the "tan" module. This pattern aligns with the clinical severity associated with ATA, ARA, and ACA. We also reviewed the associations between each module and clinical traits
185 186 187 188 189 190 191	(Extended Table 2). The Enrichment score was the highest for "mitochondrion organization" in the "turquoise" module (Figure 4C). The enrichment scores for "regulation of cellular response to stress" were highest in the "turquoise" module, moderate in the "darkmagenta" module, and lowest in the "tan" module. This pattern aligns with the clinical severity associated with ATA, ARA, and ACA. We also reviewed the associations between each module and clinical traits (Figure 4D). The "turquoise" module was positively linked to ATA, a higher modified

194 Questionnaire (HAQ) scores and lower 36-Item Short Form Health Survey (SF-36)

lower patient-reported quality of life, evidenced by higher Health Assessment

193

- 195 scores. The "darkmagenta" module was associated with ARA positivity and higher
- 196 forced vital capacity of the lungs, indicating a lower degree of ILD. The "tan" module
- 197 was correlated with the ACA profile but did not show any significant associations with
- 198 other clinical traits
- 199

# 200 Discussion

201	In this study, we applied our original PWAS technique subjecting serum
202	samples from SSc patients who participated in the DESIRES trial, along with sex and
203	age-matched HCs. Our findings revealed a significant elevation in the overall amount of
204	autoantibodies in SSc patients compared to HCs (Figure 1). We identified 58
205	autoantibodies as clinically relevant candidates in SSc, which showed a strong response
206	to B-cell depletion therapy (Figure 2). Gene ontology analysis highlighted
207	autoantibodies targeting membranous proteins, including transmembrane transporters
208	and GPCRs (Figure 3). Most of them were clustered in the same module identified by
209	WGCNA, which was significantly associated with ATA positivity, higher mRSS, and
210	lower patient-reported quality of life (Figure 4). We demonstrated the nearly perfect
211	distinction between SSc and HC samples achieved through machine learning (Table 2),
212	and SSc patients who show good response to RTX treatment engaging the clinically
213	relevant autoantibodies highlighted in our analyses (Figure 2H). These results
214	underscore the effectiveness of our integrating systems-based comprehensive
215	autoantibody screening and bioinformatic analyses, which could be called as
216	"autoantigenomics." <sup>29</sup>

217	Our machine learning analysis confirmed the prominence of well-known
218	SSc-specific ANAs such as ATA and ARA (Extended Figure 2). However, these
219	autoantibodies did not exhibit longitudinal changes during the clinical trial nor
220	differences between HRs and LRs to RTX treatment (Figure 1F and Extended Figure
221	<b>1B</b> ), consistent with our previous findings. <sup><math>13,14</math></sup> In contrast, we observed that changes in
222	the overall levels of autoantibodies were significantly correlated with RTX efficacy
223	(Figure 1, C and E). This discrepancy led us to investigate autoantibodies that exhibit
224	significant associations with the time course and drug response to RTX therapy. While
225	predictive factors for RTX responsiveness have been limited to clinical indicators such
226	as CD19-positive cell counts, mRSS, and serum levels of SP-D, <sup>30</sup> the clinically relevant
227	autoantibodies we identified were able to discriminate between HRs and LRs with high
228	accuracy (Figure 2H). Interestingly, some of these autoantibodies targeted membranous
229	antigens (Figure 3), suggesting that they are not only useful as biomarkers but also
230	could play a direct role in the pathogenesis of SSc.
231	Accumulating evidence has unveiled the relevance of autoantibodies targeting
232	GPCRs in immune-related human disorders, including SSc. <sup>31–33</sup> Notably, previous

- 233 studies have indicated the relationship between GPCRs targeted by the candidate
- autoantibodies and the pathogenesis of SSc. CCR8 is primarily expressed on Tregs

235	(Extended Figure 4C), which suppress autoimmune responses. <sup>34</sup> CC Chemokine 1
236	(CCL1) acts as a chemoattractant, recruiting Tregs to peripheral tissues by binding to
237	CCR8. <sup>35</sup> While direct evidence linking the CCR8-CCL1 axis to SSc pathogenesis is
238	lacking, blocking CCR8 could exacerbate autoimmune responses in SSc by inhibiting
239	Treg homing to target tissues. FPR1, which is abundantly expressed on neutrophils
240	(Extended Figure 4D), induces inflammation when bound by its cognate ligands. <sup>36</sup>
241	One such endogenous agonist is N-formyl-methionine (fMet), a mitochondrial
242	protein-derived molecule that serves as a damage-associated molecular pattern. <sup>37</sup> Lurley
243	R et al. have shown in SSc, elevated serum fMet levels and fMet-induced activation of
244	neutrophils through FPR1-dependent mechanisms. <sup>38</sup> Consistent with these findings, our
245	enrichment analysis highlighted mitochondrion-associated antigens targeted by
246	autoantibodies in SSc (Figure 4C), suggesting mitochondrial destruction, which has
247	also been reported in other autoimmune conditions such as systemic lupus
248	erythematosus and rheumatoid arthritis. MC1R is expressed on various cell types
249	(Extended Figure 4B), including melanocytes, inflammatory cells, endothelial cells, <sup>39</sup>
250	and skin fibroblasts from SSc patients. <sup>40</sup> Its endogenous ligand,
251	$\alpha$ -melanocyte-stimulating hormone, induces melanin production in melanocytes and
252	promotes anti-inflammatory responses, such as inhibition of nuclear factor- $\kappa B$ and

253	suppression of pro-inflammatory cytokines. <sup>41</sup> Kondo M et al. demonstrated that
254	dersimelagon (MT-7117), an oral MC1R agonist, has favorable effects on inflammation,
255	vascular dysfunction, and fibrosis, which are key pathologies in preclinical SSc
256	models. <sup>42</sup> This prompted a phase 2 clinical trial to evaluate the efficacy and tolerability
257	of MT-7117 in patients with early, progressive diffuse cutaneous SSc (NCT04440592).
258	Collectively, accumulating experimental and clinical evidence suggests that modulating
259	these GPCRs, either through stimulation or blockade, could potentially alter SSc disease
260	severity.
261	Meanwhile, it is important to note that the serum levels of the candidate

262 autoantibodies we identified were relatively modest compared to conventional 263 SSc-specific autoantibodies like ATA (Extended Figure 1B). Moreover, the presence 264 of these candidate autoantibodies did not appear to be specific to SSc, as indicated by 265 data from UT-ABCD (Extended Figure 3A and 3B). These suggest that the 266 pathogenesis of SSc may not be attributed to a single unique autoantibody that shows 267 strong cross-reactivity with conventional SSc-specific autoantibodies, but rather to a 268 collaboration of multiple autoantibodies. This hypothesis aligns with several 269 observations that suggest that SSc is a multifactorial disease, involving a combination 270 of various autoantibodies and other factors rather than a single causative factor. First,

genome-wide association studies have not identified a single gene mutation strongly
linked to SSc.<sup>43</sup> Second, the disease concordance in twins is modest and similar
between monozygotic and dizygotic twins, further supporting the notion that SSc is not
caused only by genetic factors.<sup>44</sup> Finally, and most importantly, the clinical
manifestations of SSc are highly heterogeneous.<sup>1</sup>

276 Alternatively, a cluster of several autoantibodies, with combinations that vary among patients, might explain the heterogeneity of clinical manifestations in SSc.<sup>45</sup> 277 278 Co-localization of ATA and candidate autoantibodies within the same module identified 279 by WGCNA, as well as the distribution of ATA, ARA, and ACA among different 280 modules (Figure 4), support this hypothesis. Such clustering of autoantibodies might result from cross reaction with a single specific exogenous antigen such as viruses,<sup>46,47</sup> 281 282 or intermolecular epitope spreading, a phenomenon we have recently demonstrated to 283 be involved in SSc progression using the same WPA system. Further research is needed 284 to unravel the relationships among these autoantibodies and their collective contribution 285 to SSc development. This research should include comparisons of structural similarity 286 and epitope mapping for the relevant antigens, and longitudinal serological monitoring 287 in each case. Understanding these interactions will be crucial for comprehensively

elucidating the mechanisms underlying the autoimmune aspect of SSc and potentiallyidentifying new therapeutic targets.

290 Our study has several notable strengths. Firstly, the data presented is derived 291 from a prospective, randomized, placebo-controlled clinical trial, which includes two 292 time points (before and after RTX therapy). This adherence to good clinical practice 293 ensures high data accuracy. Secondly, the use of the wheat-germ in vitro protein 294 synthesis system and the manipulation technique for WPAs enabled high-throughput 295 expression of a variety of human proteins, including membranous proteins, on a single platform.<sup>18</sup> As a result, our autoantibody measurement could encompass a wider range 296 297 of antigens at an almost proteome-wide level, allowing for the application of omics-based bioinformatics approaches to interpret the data.<sup>24</sup> Meanwhile, one major 298 299 limitation is the lack of functional assays both in vitro and in vivo. Further investigation 300 is needed to determine whether the candidate autoantibodies we identified act as 301 agonists or antagonists to their target proteins, and whether they influence the 302 pathophysiology of SSc. Moreover, the value of autoantibodies we identified for 303 predicting treatment response to RTX should be validated in external cohorts in 304 real-world clinical settings.

305

# 306 **References**

307	1.	Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Prim. 1, 1-21 (2015).
308	2.	Rubio-Rivas, M., Royo, C., Simeón, C. P., Corbella, X. & Fonollosa, V.
309		Mortality and survival in systemic sclerosis: Systematic review and
310		meta-analysis. Semin. Arthritis Rheum. 44, 208–219 (2014).
311	3.	Hasegawa, M. et al. B-lymphocyte depletion reduces skin fibrosis and
312		autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol.
313		<b>169</b> , 954–66 (2006).
314	4.	Numajiri, H. et al. B Cell Depletion Inhibits Fibrosis via Suppression of
315		Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis.
316		Arthritis Rheumatol. 73, 2086–2095 (2021).
317	5.	Fukasawa, T. et al. Single-cell-level protein analysis revealing the roles of
318		autoantigen-reactive B lymphocytes in autoimmune disease and the murine
319		model. doi:10.7554/eLife.
320	6.	Daoussis, D. et al. A multicenter, open-label, comparative study of B-cell
321		depletion therapy with Rituximab for systemic sclerosis-associated interstitial
322		lung disease. Semin. Arthritis Rheum. 46, 625–631 (2017).

323	7.	Sircar, G., Goswami, R. P., Sircar, D., Ghosh, A. & Ghosh, P. Intravenous
324		cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma
325		lung disease: Open label, randomized, controlled trial. Rheumatol. (United
326		Kingdom) <b>57</b> , 2106–2113 (2018).
327	8.	Ebata, S. et al. Rituximab therapy is more effective than cyclophosphamide
328		therapy for Japanese patients with anti-topoisomerase I-positive systemic
329		sclerosis-associated interstitial lung disease. J. Dermatol. 46, 1006–1013 (2019).
330	9.	Einhaus, J. et al. Inhibition of effector B cells by ibrutinib in systemic sclerosis.
331		Arthritis Res. Ther. 22, 1–8 (2020).
332	10.	Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc)
333		using CD19-targeted CAR T cells. Ann. Rheum. Dis. 82, 1117–1120 (2023).
334	11.	Merkt, W. et al. Third-generation CD19.CAR-T cell-containing combination
335		therapy in Scl70+ systemic sclerosis. Ann. Rheum. Dis. 83, 543 LP – 546 (2024).
336	12.	Fabian, M. et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case
337		Series with Follow-up. N. Engl. J. Med. 390, 687-700 (2024).
338	13.	Ebata, S. et al. Safety and efficacy of rituximab in systemic sclerosis
339		(DESIRES): a double-blind, investigator-initiated, randomised,
340		placebo-controlled trial. Lancet Rheumatol. 3, e489-e497 (2021).

341	14.	Ebata, S.	et al.	Safety	and efficacy	of rituxima	b in syst	emic sclerosi	S
-----	-----	-----------	--------	--------	--------------	-------------	-----------	---------------	---

- 342 (DESIRES): open-label extension of a double-blind, investigators-initiated,
- 343 randomised, placebo-controlled trial. *Lancet Rheumatol.* **4**, e546–e555 (2022).
- 344 15. Kuzumi, A. et al. Long-term Outcomes After Rituximab Treatment for Patients
- 345 With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on
- 346 Serum Immunoglobulin Levels. *JAMA Dermatology* **159**, 374–383 (2023).
- 347 16. Okano, Y. Antinuclear antibody in systemic sclerosis (scleroderma). *Rheum Dis*
- 348 *Clin North Am* 22, 709–35 (1996).
- 349 17. Nihtyanova, S. I. & Denton, C. P. Autoantibodies as predictive tools in systemic

350 sclerosis. *Nat. Rev. Rheumatol.* **6**, 112–116 (2010).

- 351 18. Goshima, N. et al. Human protein factory for converting the transcriptome into
- an in vitro-expressed proteome. *Nat. Methods* 5, 1011–1017 (2008).
- 353 19. Fukuda, E. et al. Identification and characterization of the antigen recognized by
- the germ cell mAb TRA98 using a human comprehensive wet protein array.
- 355 *Genes to Cells* **26**, 180–189 (2021).
- 356 20. Matsuda, K. M. et al. Autoantibody Landscape Revealed by Wet Protein
- 357 Array□: Sum of Autoantibody Levels Re fl ects Disease Status. *Front. Immunol.*
- **358 13**, 1–14 (2022).

359	21.	Kuzumi, A. et al. Comprehensive autoantibody profiling in systemic
360		autoimmunity by a highly-sensitive multiplex protein array. Front. Immunol. 14,
361		(2023).
362	22.	Matsuda, K. M., Kotani, H., Yamaguchi, K., Okumura, T. & Fukuda, E.
363		Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis
364		revealed by proteome-wide autoantibody screening. J. Autoimmun. 135, 102995
365		(2023).
366	23.	Matsuda, K. M. et al. Autoantibodies to nuclear valosin-containing protein-like
367		protein: systemic sclerosis-specific antibodies revealed by in vitro human
368		proteome. Rheumatology (Oxford). (2024) doi:10.1093/rheumatology/keae063.
369	24.	Matsuda, K. M. et al. Proteome-wide autoantibody screening and holistic
370		autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape.
371		medRxiv 2024.06.07.24308592 (2024) doi:10.1101/2024.06.07.24308592.
372	25.	Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis
373		of systems-level datasets. Nat. Commun. 10, 1523 (2019).
374	26.	Fagerberg, L. et al. Analysis of the human tissue-specific expression by
375		genome-wide integration of transcriptomics and antibody-based proteomics. Mol.
376		Cell. Proteomics 13, 397–406 (2014).

	377	27.	The Tabula Sapiens Consortium. The Tabula Sapiens: A multiple-organ
--	-----	-----	---

- 378 single-cell transcriptomic atlas of humans. *Science* (80-. ). 376, eabl4896 (2022).
- 28. Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation
- anetwork analysis. *BMC Bioinformatics* **9**, (2008).
- 381 29. Moritz, C. P. *et al.* Autoantigenomics: Holistic characterization of autoantigen
- 382 repertoires for a better understanding of autoimmune diseases. *Autoimmun. Rev.*
- **383 19**, 102450 (2020).
- 384 30. Matsuda, K. M. *et al.* Development of a prediction model of treatment response
- in patients with cutaneous arteritis : Insights from a cohort of 33 patients. J.
- 386 *Dermatol.* 48, 1021–1026 (2021).
- 387 31. Cabral-Marques, O. et al. GPCR-specific autoantibody signatures are associated
- 388 with physiological and pathological immune homeostasis. *Nat. Commun.* 9, 5224
- 389 (2018).
- 390 32. Cabral-marques, O. et al. Autoantibodies targeting GPCRs and RAS-related
- 391 molecules associate with COVID-19 severity. *Nat. Commun.* **13**, 1220 (2022).
- 392 33. Akbarzadeh, R., Müller, A., Humrich, J. Y. & Riemekasten, G. When natural
- antibodies become pathogenic: autoantibodies targeted against G

394	protein-cour	oled rece	ptors in the	nathogenesis	of s	vstemic sclei	rosis Front
001	protein coup		prois in the	pullogenesis	OI B	ysterine serei	10010. 1 10111.

- 395 *Immunol.* 14, 1213804 (2023).
- 396 34. Barsheshet, Y. *et al.* CCR8+FOXp3+ Treg cells as master drivers of immune
- 397 regulation. Proc. Natl. Acad. Sci. 114, 6086–6091 (2017).
- 398 35. Tiffany, H. L. *et al.* Identification of CCR8: a human monocyte and thymus
- 399 receptor for the CC chemokine I-309. J. Exp. Med. 186, 165–170 (1997).
- 400 36. Mcdonald, B. et al. Intravascular Danger Signals Guide Neutrophils to Sites of
- 401 Sterile Inflammation. *Science* (80-. ). **330**, 362–367 (2011).
- 402 37. Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses
- 403 to injury. *Nature* 464, 104–107 (2010).
- 404 38. Napolitano, F. et al. N-formyl peptide receptors induce radical oxygen
- 405 production in fibroblasts derived from systemic sclerosis by interacting with a
- 406 cleaved form of urokinase receptor. *Front. Immunol.* **9**, (2018).
- 407 39. Getting, S. J. Targeting melanocortin receptors as potential novel therapeutics.
- 408 *Pharmacol. Ther.* **111**, 1–15 (2006).
- 409 40. Kokot, A. *et al.* α-melanocyte–stimulating hormone suppresses
- 410 bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse

411		model of scleroderma: Melanocortin peptides as a novel treatment strategy for
412		scleroderma? Arthritis Rheum. 60, 592-603 (2009).
413	41.	Wang, W., Guo, DY., Lin, YJ. & Tao, YX. Melanocortin Regulation of
414		Inflammation. Front. Endocrinol. (Lausanne). 10, (2019).
415	42.	Kondo, M. et al. Dersimelagon, a novel oral melanocortin 1 receptor agonist,
416		demonstrates disease-modifying effects in preclinical models of systemic
417		sclerosis. Arthritis Res. Ther. 24, 1–17 (2022).
418	43.	Ishikawa, Y. et al. GWAS for systemic sclerosis identifies six novel
419		susceptibility loci including one in the Fcy receptor region. Nat. Commun. 15,
420		319 (2024).
421	44.	Feghali-Bostwick, C., Medsger, T. A. J. & Wright, T. M. Analysis of systemic
422		sclerosis in twins reveals low concordance for disease and high concordance
423		for the presence of antinuclear antibodies. Arthritis Rheum. 48, 1956–1963
424		(2003).
425	45.	Kuzumi, A., Norimatsu, Y. & Matsuda, K. M. Comprehensive autoantibody pro
426		fi ling in systemic autoimmunity by a highly- sensitive multiplex protein array.
427		1–14 (2023) doi:10.3389/fimmu.2023.1255540.

428	46.	Lunardi, C. et al. Systemic sclerosis immunoglobulin G autoantibodies bind the
429		human cytomegalovirus late protein UL94 and induce apoptosis in human
430		endothelial cells. Nat. Med. 6, 1183–1186 (2000).
431	47.	Ohtsuka, T. & Yamazaki, S. Increased prevalence of human parvovirus B19
432		DNA in systemic sclerosis skin. Br. J. Dermatol. 150, 1091–1095 (2004).
433	48.	Ho, D., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric Preprocessing
434		for Parametric Causal Inference. J. Stat. Softw. 42, 1-28 (2011).
435	49.	Khanna, D. et al. Standardization of the modified Rodnan skin score for use in
436		clinical trials of systemic sclerosis. J. Scleroderma Relat. Disord. 2, 11–8 (2017).
437	50.	Khanna, D. et al. Minimally important difference in diffuse systemic sclerosis:
438		results from the D-penicillamine study. Ann. Rheum. Dis. 65, 1325–1329 (2006).
439		

440

# 441 Acknowledgements

442	We thank Ms. Maiko Enomoto and her colleagues for their secretarial work.
443	We appreciate K. Yamaguchi, T. Okumura, C. Ono, A. Sato, A. Miya, and N. Goshima
444	from ProteoBridge Corporation for preparing the WPAs. We also acknowledge R.
445	Uchino, Y. Murakami, and H. Matsunaka from TOKIWA Pharmaceuticals Co. Ltd. for
446	providing technical assistance with autoantibody measurement.

### 447 Author Contributions

448	KM Matsuda primarily engaged in autoantibody measurement, clinical data
449	collection, data analysis, visualization, and writing the first draft of the manuscript. K
450	Iwadoh participated in machine learning analysis. S Ebata was primarily engaged in the
451	management of SSc patients participated in the DESIRES trial. H Kotani, A Kuzumi, T
452	Fukasawa, A Yoshizaki-Ogawa took part in the sample collection of SSc. S Sato
453	conceptualized and supervised the study. A Yoshizaki conceptualized, launched, and
454	supervised this study, and was involved in revising the manuscript.
455	

## 456 Conflict-of-interest statement

457	T Fukasawa and A Yoshizaki belong to the Social Cooperation Program,
458	Department of Clinical Cannabinoid Research, The University of Tokyo Graduate
459	School of Medicine, Tokyo, Japan, supported by Japan Cosmetic Association and Japan
460	Federation of Medium and Small Enterprise Organizations. The remaining authors
461	declare that the research was conducted in the absence of any commercial or financial
462	relationships that could be construed as a potential conflict of interest.
463	

#### 464 Materials and Methods

465 *Study Design* 

466 The study design for the DESIRES trial has been previously reported (NCT04274257).<sup>13</sup> Briefly, the DESIRES trial was a randomized, double-blind, 467 468 placebo-controlled trial of 24 weeks. In total, 56 patients were randomized to receive either intravenous rituximab (375 mg/m<sup>2</sup>) or matching placebo once per week for 4 469 470 weeks. Of these, 49 patients completed the double-blind phase. Serum samples were 471 collected and served for PWAS at the beginning and the end of the double-blind phase 472 (Fig. 1A). After excluding 4 cases due to their serum unsuitable for PWAS, data of 45 473 patients were included in our analysis. Age and sex matched HCs were selected from a 474 cohort of healthcare providers on annual checkups without any medical history (Fig. **1B**), using "matchIt" R package.<sup>48</sup> This study was approved by the ethics committee of 475 476 the University of Tokyo Graduate School of Medicine and conducted in accordance 477 with the Declaration of Helsinki. Written informed consent was obtained from all 478 patients.

479

480 Assessments

481	Clinical and laboratory assessments were performed at baseline and at 24
482	weeks after the first infusion of rituximab. Skin sclerosis was assessed by mRSS. <sup>49</sup>
483	Lung function was evaluated by pulmonary function tests. Serum levels of Krebs von
484	den Lungen-6 (KL-6; normal range: 0-500 U/mL) and surfactant protein-D (SP-D;
485	normal range: 0-110 ng/mL), which are glycoproteins mainly produced by type II
486	pneumocytes, were measured as established markers of ILD in patients with SSc.
487	Laboratory examinations included white blood cell count, lymphocyte count, the
488	number of CD19 <sup>+</sup> and CD20 <sup>+</sup> cells, and serum levels of IgG (normal range: 700-1600
489	mg/dL), IgM (normal range: 40-250 mg/dL), and IgA (normal range: 70-400 mg/dL).
490	Patients with mRSS improvement of 7 or higher and 6 or lower were classified as HRs
491	and LRs, respectively, based on the previous study on minimally important differences
492	for mRSS. <sup>50</sup> This classification resulted in 16 high responders and 13 LRs (Fig. 1C).
493	

# 494 Autoantibody measurement

WPAs were arranged as previously described.<sup>20</sup> First, proteins were
synthesized *in vitro* utilizing a wheat germ cell-free system from 13,455 clones of the
HuPEX.<sup>18</sup> Second, synthesized proteins were plotted onto glass plates (Matsunami
Glass, Osaka, Japan) in an array format by the affinity between the GST-tag added to

499	the N-terminus of each protein and glutathione modified on the plates. The WPAs were
500	treated with human serum diluted by 3:1000 in the reaction buffer containing 1x
501	Synthetic block (Invitrogen), phosphate-buffered saline (PBS), and 0.1% Tween 20.
502	Next, the WPAs were washed, and goat anti-Human IgG (H+L) Alexa Flour 647
503	conjugate (Thermo Fisher Scientific, San Jose, CA, USA) diluted 1000-fold was added
504	to the WPAs and reacted for 1 hour at room temperature. Finally, the WPAs were
505	washed, air-dried, and fluorescent images were acquired using a fluorescence imager
506	(Typhoon FLA 9500, Cytiva, Marlborough, MA, USA). Fluorescence images were
507	analyzed to quantify serum levels of autoantibodies targeting each antigen, following
508	the formula shown below:

Autoantibody level 
$$[AU] = \frac{F_{autoantigen} - F_{negative control}}{F_{positive control} - F_{negative control}} \times 100$$

- *AU*: arbitrary unit
- $F_{autoantigen}$ : fluorescent intensity of autoantigen spot
- *F*<sub>negative control</sub>. fluorescent intensity of negative control spot
- *F* positive control. fluorescent intensity of positive control spot

515 Machine learning

516	We applied supervised machine learning techniques using the Python code
517	with the scikit-learn library to analyze the autoantibody measurement data. With the
518	random forest model, decision trees were built and trained in parallel on subsets of
519	sampled instances and features. Meanwhile, with the XGBoost model, decision trees
520	were built sequentially to improve each other. The final prediction of the random forest
521	was based on the majority of its decision trees, while that of XGBoost was derived from
522	their weighted average. The performance of the classifiers was evaluated using the area
523	under the operator-receiver characteristics curve (AUC), accuracy, precision, recall, and
524	F1-score, with the higher the scores indicating the better classification performance. The
525	accuracy is the ratio of the correct positive and negative prediction, the precision is the
526	ratio of the correct positive prediction, the recall (or sensitivity) is the ratio of the
527	correct positive prediction among all true positive instances, and F1-score is the
528	harmonic mean of precision and sensitivity.

529

#### 530 WGCNA analysis

531 The weighted gene co-expression network was constructed using the
532 "WGCNA" R package.<sup>28</sup> We calculated each gene pair's Pearson correlation coefficient,
533 measured how similarly their expressions were expressed, and created a correlation

534	matrix. Scale-free topology requirements were used to compute the "soft" threshold
535	power to build biologically meaningful scale-free networks. Based on the adjacency
536	matrix, dynamic tree cuts and at least 100 genes per module were utilized to generate a
537	topological overlap matrix for co-expression modules. In addition, we assessed gene
538	significance, module membership, and correlated modules with clinical characteristics
539	and mapped signature genes.
540	
541	Statistical analysis
542	Fisher exact test was performed to compare categorical variables.
543	Mann-Whitney U test or Wilcoxon signed-rank test as appropriate was performed to
544	compare continuous variables. Spearman correlation test was used for correlation
545	analysis. P values of $<.05$ were considered statistically significant. Gene Ontology
546	Analysis using web-based tools targeted the list of the entry clones coding the
547	differentially highlighted autoantigens was performed for gene-list enrichment analysis,
548	gene-disease association analysis, and transcriptional regulatory network analysis with
549	Metascape. <sup>25</sup> Data analyses were conducted using R (v4.2.1).
550	

551 Data visualization

552	Box plots, scatter plots, hierarchical clustering, and correlation matrix were
553	visualized by using R (v4.2.1). Box plots were defined as follows: the middle line
554	corresponds to the median; the lower and upper hinges correspond to the first and third
555	quartiles; the upper whisker extends from the hinge to the largest value no further than
556	1.5 times the interquartile range (IQR) from the hinge; and the lower whisker extends
557	from the hinge to the smallest value at most 1.5 times the IQR of the hinge.

558

#### **Figure legends**

**Figure 1. Overview of the study.** (A) The study design of the DESIRES trial. (B) The flow chart of sample acquisition in the present study. (C) The sum of autoantibody levels (SAL) in SSc at the baseline and HCs. (D) Absolute change of mRSS in SSc patients during the DESIREs trial. HR: high responder, LR: low responder. (E) SAL before and after the study period of the DESIRES trial by the treatment arm. (F) Serum levels of SSc-related autoantibodies before and after the study period of the DESIRES trial by the treatment arm. ATA: anti-topoisomerase I antibody, ACA: anti-centromere antibody, ARA: anti-RNA polymerase III antibody. \*: P < 0.05, \*\*\*\*: P < 0.0001, NS: P > 0.05. P values were calculated by Mann-Whitney's U test.

#### Figure 2. Selection of autoantibodies of clinical relevance.

(A) Volcano plot that shows autoantibodies differentially elevated in SSc before treatment compared to HCs. The vertical dash line indicates P = 0.05. (B) Volcano plot that shows autoantibodies differentially increased in HRs than in LRs. (C) Volcano plot that shows autoantibodies significantly reduced in HRs during RTX therapy. (D) Heat map that shows the serum levels of 58 candidate autoantibodies of clinical relevance. (E) Principal component analysis of 58 candidate autoantibodies of clinical relevance. In the scatter plot, individual subjects as points. The loading diagram illustrates the contributions to PC1 and PC2. (F) SAL focused on 58 candidate autoantibodies of clinical relevance. \*\*\*: P < 0.001, \*\*\*\*: P < 0.0001, NS: P > 0.05. P values were calculated by Mann-Whitney's U test. (G) The receiver-operator characteristics (ROC) curve demonstrating the discrimination between SSc and HCs by all the measured autoantibodies (green) and by 58 candidate autoantibodies of clinical relevance (yellow). (H) The ROC curve demonstrating the discrimination between HRs and LRs by all the measured autoantibodies (green) and by 58 candidate autoantibodies of clinical relevance (yellow).

#### Figure 3. Proteins targeted by the candidate autoantibodies of clinical relevance.

(A) Gene ontology analysis encompassing the genes coding proteins targeted the candidate autoantibodies. (B) The circos plot represents the inclusion relationship between each gene ontology and the candidate autoantibodies. (C) Serum levels of candidate autoantibodies associated with "import across plasma membrane." (D) The heatmap illustrates correlation between the candidate autoantibodies associated with "import across plasma membrane." (D) The heatmap illustrates correlation between the candidate autoantibodies associated with "import across plasma membrane" and clinical traits of SSc. (E) Serum levels of autoantibodies associated with "peptide GPCRs." (F) The heatmap illustrates correlation between the candidate autoantibodies associated with "peptide GPCRs." and clinical traits of SSc. \*: P < 0.05, \*\*: P < 0.01, \*\*\*: P < 0.001. P values were calculated by Spearman's correlation test.

**Figure 4. WGCNA analysis.** (**A**) Network heatmap plot. Branches in the hierarchical clustering dendrograms correspond to modules. Color-coded module membership is displayed in the color bars below and to the right of the dendrograms. In the heatmap, high co-expression interconnectedness is indicated by progressively more saturated yellow and red colors. (**B**) Gene ontology analysis encompassing the genes coding proteins targeted by autoantibodies included in the "turquoise," "darkmagenta," and "tan" modules. (**C**) The heat map illustrates correlation between each module identified by WGCNA analysis and clinical traits of SSc. (**D**) The heatmap shows the correlation between each module and clinical trait. \*: P < 0.05, \*\*: P < 0.01, \*\*\*: P < 0.001. P values were calculated by Spearman's correlation test.

# Extended Figure 1. Additional results of PWAS. (A) The sum of autoantibody levels

(SAL) by age groups. (B) Serum levels of SSc-related autoantibodies before and after

the DESIRES trial by the treatment arm and responsiveness.

#### Extended Figure 2. Autoantibodies highlighted in each machine learning model.

(A) Autoantibodies that were mostly highlighted according to feature importance by Lasso regression, Ridge regression, SVM with normalization, Random Forest, XGBoost, and LightGBM. (B) The inclusion relationship of autoantibodies highlighted by the six machine learning frameworks illustrated by an UpSet plot. (C) The box plots describe the serum levels of autoantibodies highlighted by more than two frameworks in COVID-19, atopic dermatitis (AD), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and healthy controls (HCs). The data derives from the UT-ABCD.

#### Extended Figure 3. Distribution of the candidate autoantibodies among various

**disorders.** The box plots describe the serum levels of the candidate autoantibodies associated with "import across plasma membrane" (**A**) and "peptide GPCRs" (**B**) in COVID-19, atopic dermatitis (AD), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and healthy controls (HCs). The data derives from the UT-ABCD.

#### Extended Figure 4. Expression of highlighted autoantigens in human tissues and

**single cells.** Expression of autoantigens associated with "import across plasma membrane" (**A**) or with "peptide GPCRs" (**B**) in multiple human tissues, as measured by bulk RNA-sequencing from the Human Protein Atlas. Expression of CCR8 (**C**) or FPR1 (**D**) in immune cells from multiple human tissues, as measured by single-cell RNA-sequencing from the Tabula Sapiens project.





Figure 2

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-ND 4.0 International license.

# Gene Ontology Analysis



GO:0098739: import across plasma membrane WP24: Peptide GPCRs GO:0006281: DNA repair GO:1904063: negative regulation of cation transmembrane transport GO:0043467: regulation of generation of precursor metabolites and energy GO:0043484: regulation of RNA splicing R-HSA-112316: Neuronal System

В

Α

	PSEN1	SLC22A2	TRPV5	SLC46A1	CCR8	FPR1	MC1R	GPR63
GO:00983739								
WP24								
GO:0006281								
GO:1904063								
GO:0043467								
GO:0043484								
R-HSA-112316								









Matsuda KM et al. Figure 3

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is madeavailable under a CC-BY-ND 4.0 International license.



	АТА	ARA	ACA	PSEN1	SLC22 A2	TRPV5	SLC46 A1	CCR8	FPR1	MC1R	
turquoise											
darkmagenta											
tan											Γ

GPR63

В

